GSK:NYE-GlaxoSmithKline PLC

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 37.92

Change

+0.42 (+1.12)%

Market Cap

USD 94.00B

Volume

7.44M

Yahoo Analyst Target

USD 42.72 (12.66%)

STA Analyst Target

USD 42.67 (12.52%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing GSK

PPH VanEck Vectors Pharmaceut.. 4.85 % 0.35 %

-0.10 (-0.46%)

USD 0.30B
HHL:CA Healthcare Leaders Income.. 4.81 % 1.37 %

-0.04 (-0.46%)

CAD 0.26B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.91% 74% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.91% 74% C 85% B
Trailing 12 Months  
Capital Gain -3.31% 26% F 22% F
Dividend Return 5.22% 100% A+ 69% D+
Total Return 1.91% 30% F 25% F
Trailing 5 Years  
Capital Gain -13.68% 17% F 26% F
Dividend Return 26.15% 87% B+ 75% C
Total Return 12.47% 28% F 33% F
Average Annual (5 Year Horizon)  
Capital Gain -4.96% 22% F 15% F
Dividend Return 0.05% 26% F 19% F
Total Return 5.01% 100% A+ 73% C
Risk Return Profile  
Volatility (Standard Deviation) 10.16% 87% B+ 69% D+
Risk Adjusted Return 0.52% 26% F 19% F
Market Capitalization 92.50B 64% D 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.83 39% F 23% F
Price/Book Ratio 86.18 4% F 1% F
Price / Cash Flow Ratio 2.56 78% C+ 53% F
Price/Free Cash Flow Ratio 15.35 74% C 44% F
Management Effectiveness  
Return on Equity 190.83% 100% A+ 99% A+
Return on Invested Capital 27.63% 96% A 91% A-
Return on Assets 4.00% 52% F 63% D
Debt to Equity Ratio 1,635.00% 5% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.